FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362471767> ?p ?o ?g. }

• W4362471767 abstract "Major depression and other depressive conditions are common in people with cancer. These conditions are not easily detectable in clinical practice, due to the overlap between medical and psychiatric symptoms, as described by diagnostic manuals such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD). Moreover, it is particularly challenging to distinguish between pathological and normal reactions to such a severe illness. Depressive symptoms, even in subthreshold manifestations, have a negative impact in terms of quality of life, compliance with anticancer treatment, suicide risk and possibly the mortality rate for the cancer itself. Randomised controlled trials (RCTs) on the efficacy, tolerability and acceptability of antidepressants in this population are few and often report conflicting results.To evaluate the efficacy, tolerability and acceptability of antidepressants for treating depressive symptoms in adults (aged 18 years or older) with cancer (any site and stage).We used standard, extensive Cochrane search methods. The latest search date was November 2022.We included RCTs comparing antidepressants versus placebo, or antidepressants versus other antidepressants, in adults (aged 18 years or above) with any primary diagnosis of cancer and depression (including major depressive disorder, adjustment disorder, dysthymic disorder or depressive symptoms in the absence of a formal diagnosis).We used standard Cochrane methods. Our primary outcome was 1. efficacy as a continuous outcome. Our secondary outcomes were 2. efficacy as a dichotomous outcome, 3. Social adjustment, 4. health-related quality of life and 5. dropouts. We used GRADE to assess certainty of evidence for each outcome.We identified 14 studies (1364 participants), 10 of which contributed to the meta-analysis for the primary outcome. Six of these compared antidepressants and placebo, three compared two antidepressants, and one three-armed study compared two antidepressants and placebo. In this update, we included four additional studies, three of which contributed data for the primary outcome. For acute-phase treatment response (six to 12 weeks), antidepressants may reduce depressive symptoms when compared with placebo, even though the evidence is very uncertain. This was true when depressive symptoms were measured as a continuous outcome (standardised mean difference (SMD) -0.52, 95% confidence interval (CI) -0.92 to -0.12; 7 studies, 511 participants; very low-certainty evidence) and when measured as a proportion of people who had depression at the end of the study (risk ratio (RR) 0.74, 95% CI 0.57 to 0.96; 5 studies, 662 participants; very low-certainty evidence). No studies reported data on follow-up response (more than 12 weeks). In head-to-head comparisons, we retrieved data for selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs) and for mirtazapine versus TCAs. There was no difference between the various classes of antidepressants (continuous outcome: SSRI versus TCA: SMD -0.08, 95% CI -0.34 to 0.18; 3 studies, 237 participants; very low-certainty evidence; mirtazapine versus TCA: SMD -4.80, 95% CI -9.70 to 0.10; 1 study, 25 participants). There was a potential beneficial effect of antidepressants versus placebo for the secondary efficacy outcomes (continuous outcome, response at one to four weeks; very low-certainty evidence). There were no differences for these outcomes when comparing two different classes of antidepressants, even though the evidence was very uncertain. In terms of dropouts due to any cause, we found no difference between antidepressants compared with placebo (RR 0.85, 95% CI 0.52 to 1.38; 9 studies, 889 participants; very low-certainty evidence), and between SSRIs and TCAs (RR 0.83, 95% CI 0.53 to 1.22; 3 studies, 237 participants). We downgraded the certainty of the evidence because of the heterogeneous quality of the studies, imprecision arising from small sample sizes and wide CIs, and inconsistency due to statistical or clinical heterogeneity.Despite the impact of depression on people with cancer, the available studies were few and of low quality. This review found a potential beneficial effect of antidepressants against placebo in depressed participants with cancer. However, the certainty of evidence is very low and, on the basis of these results, it is difficult to draw clear implications for practice. The use of antidepressants in people with cancer should be considered on an individual basis and, considering the lack of head-to-head data, the choice of which drug to prescribe may be based on the data on antidepressant efficacy in the general population of people with major depression, also taking into account that data on people with other serious medical conditions suggest a positive safety profile for the SSRIs. Furthermore, this update shows that the usage of the newly US Food and Drug Administration-approved antidepressant esketamine in its intravenous formulation might represent a potential treatment for this specific population of people, since it can be used both as an anaesthetic and an antidepressant. However, data are too inconclusive and further studies are needed. We conclude that to better inform clinical practice, there is an urgent need for large, simple, randomised, pragmatic trials comparing commonly used antidepressants versus placebo in people with cancer who have depressive symptoms, with or without a formal diagnosis of a depressive disorder." @default.
• W4362471767 created "2023-04-05" @default.
• W4362471767 creator A5018274416 @default.
• W4362471767 creator A5039199295 @default.
• W4362471767 creator A5049874666 @default.
• W4362471767 creator A5053129482 @default.
• W4362471767 creator A5073296001 @default.
• W4362471767 date "2023-03-31" @default.
• W4362471767 modified "2023-10-11" @default.
• W4362471767 title "Antidepressants for the treatment of depression in people with cancer" @default.
• W4362471767 cites W1051008347 @default.
• W4362471767 cites W114368807 @default.
• W4362471767 cites W130054925 @default.
• W4362471767 cites W1480403177 @default.
• W4362471767 cites W1512303533 @default.
• W4362471767 cites W1521227887 @default.
• W4362471767 cites W1527903768 @default.
• W4362471767 cites W1535209921 @default.
• W4362471767 cites W1557078286 @default.
• W4362471767 cites W1591259115 @default.
• W4362471767 cites W1593061374 @default.
• W4362471767 cites W1608267622 @default.
• W4362471767 cites W1659048389 @default.
• W4362471767 cites W1784226620 @default.
• W4362471767 cites W1845447069 @default.
• W4362471767 cites W1890073398 @default.
• W4362471767 cites W1919034455 @default.
• W4362471767 cites W1952399110 @default.
• W4362471767 cites W1955762873 @default.
• W4362471767 cites W1959149127 @default.
• W4362471767 cites W1964162160 @default.
• W4362471767 cites W1964290581 @default.
• W4362471767 cites W1965295590 @default.
• W4362471767 cites W1967603453 @default.
• W4362471767 cites W1968000956 @default.
• W4362471767 cites W1969065116 @default.
• W4362471767 cites W1970245256 @default.
• W4362471767 cites W1971171376 @default.
• W4362471767 cites W1973820612 @default.
• W4362471767 cites W1977618336 @default.
• W4362471767 cites W1981625620 @default.
• W4362471767 cites W1986544463 @default.
• W4362471767 cites W1988430417 @default.
• W4362471767 cites W1993028853 @default.
• W4362471767 cites W1995415250 @default.
• W4362471767 cites W1997530992 @default.
• W4362471767 cites W1999672434 @default.
• W4362471767 cites W2000856095 @default.
• W4362471767 cites W2002348917 @default.
• W4362471767 cites W2003982930 @default.
• W4362471767 cites W2005696199 @default.
• W4362471767 cites W2009109621 @default.
• W4362471767 cites W2012504366 @default.
• W4362471767 cites W2013263319 @default.
• W4362471767 cites W2015045196 @default.
• W4362471767 cites W2017459421 @default.
• W4362471767 cites W2019450798 @default.
• W4362471767 cites W2020401373 @default.
• W4362471767 cites W2024331734 @default.
• W4362471767 cites W2032477348 @default.
• W4362471767 cites W2034276779 @default.
• W4362471767 cites W2037377025 @default.
• W4362471767 cites W2039324822 @default.
• W4362471767 cites W2039746812 @default.
• W4362471767 cites W204046373 @default.
• W4362471767 cites W2044384616 @default.
• W4362471767 cites W2048775918 @default.
• W4362471767 cites W2050835116 @default.
• W4362471767 cites W2053641615 @default.
• W4362471767 cites W2055930974 @default.
• W4362471767 cites W2058047967 @default.
• W4362471767 cites W2058646840 @default.
• W4362471767 cites W2058683337 @default.
• W4362471767 cites W2064063481 @default.
• W4362471767 cites W2067495470 @default.
• W4362471767 cites W2068959829 @default.
• W4362471767 cites W2070095833 @default.
• W4362471767 cites W2074014039 @default.
• W4362471767 cites W2074302276 @default.
• W4362471767 cites W2076323540 @default.
• W4362471767 cites W2077967373 @default.
• W4362471767 cites W2081176426 @default.
• W4362471767 cites W2085066156 @default.
• W4362471767 cites W2088206781 @default.
• W4362471767 cites W2089047250 @default.
• W4362471767 cites W2089110461 @default.
• W4362471767 cites W2092683646 @default.
• W4362471767 cites W2092718449 @default.
• W4362471767 cites W2095281586 @default.
• W4362471767 cites W2097313012 @default.
• W4362471767 cites W2099725757 @default.
• W4362471767 cites W2102151931 @default.
• W4362471767 cites W2104045094 @default.
• W4362471767 cites W2104981347 @default.
• W4362471767 cites W2105258029 @default.
• W4362471767 cites W2107278158 @default.
• W4362471767 cites W2108276209 @default.
• W4362471767 cites W2108924730 @default.
• W4362471767 cites W2109841849 @default.
• W4362471767 cites W2114613490 @default.

• next